Please login to the form below

serelaxin

This page shows the latest serelaxin news and features for those working in and with pharma, biotech and healthcare.

New drugs can't keep Novartis sales on the up

year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back Novartis' profits, forcing the company to take a charge of $200m in the quarter.

Latest news

What future for serelaxin after phase III miss?

Novartis' acute heart failure therapy misses two main endpoints. The failure of Novartis' acute heart failure therapy serelaxin to hit its objectives in a second phase III trial is somewhat embarrassing ... credibility". Novartis had been hoping to build
Novartis boosts cardiovascular pipeline with $1bn Ionis deal

The company launched first-in-class chronic heart failure therapy Entresto (sacubitril and valsartan) in 2015 and is hoping to re-file acute heart failure candidate serelaxin (RLX030) this year.
Novartis says Cosentyx is 'outpacing competitors'

These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.
Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a
CHMP turns down Avastin for brain cancer

heart failure drug Reasanz (serelaxin).

More from news
Approximately 8 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Other candidates in mid-stage testing include: natriuretic peptide receptor agonists from Capricor Therapeutics (cenderitide) and Palatin Technologies (PL-3994); Novartis' synthetic human relaxin 2 hormone serelaxin (knocked back by regulators
Interview: Elmar Schnee, Cardiorentis

It's a company with great potential, according to Schnee, who has high hopes for its lead drug candidate ularitide – an investigational product that is in competition with Novartis' serelaxin to ... Because of the serelaxin trial [by Novartis], you saw

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

PMHub

Add my company

The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...